Alzheimer’s disease (AD) drug research has traditionally focused on removing toxic amyloid-β (Aβ) and Tau aggregates, leading to FDA-approved anti-Aβ antibodies. However, the real-world effectiveness of these drugs is still uncertain due to the multifactorial nature of AD. There is a need to shift from single target approaches to combinatorial strategies that address multiple targets. Mitochondria play a crucial role in resilience mechanisms that maintain cellular homeostasis and impede disease progression across molecular, cellular, and brain-wide levels. A functional mitochondrial network is essential for preserving protein homeostasis, sustaining energy status, and maintaining synaptic firing rates. The MIND-AD CRE aims to coordinate interdisciplinary research to understand AD holistically and justify combinatorial treatments